Point Therapeutics' Diabetes Program Presented at the Endocrine Society Annual Meeting
June 27 2006 - 8:10AM
Business Wire
Point Therapeutics, Inc. (NASDAQ: POTP) presented a preclinical
poster on the Company's lead diabetes compound, PT-630, at the
Endocrine Society Annual Meeting on Monday, June 26, 2006. PT-630
is an inhibitor of DPP-4, which is a widely recognized target for
the treatment of diabetes. During this poster presentation, the
Company presented side-by-side experiments in Zucker Diabetic Fatty
(ZDF) rats comparing PT-630 to both a cyanopyrrolidine (CP) DPP-4
inhibitor and to metformin. These preclinical data lead the Company
to conclude that: -- With a single dose administration, PT-630
demonstrates longer term benefits in both elevation of GLP-1 levels
{24 and 48 hours post oral glucose tolerance test (OGTT)} and
lowering of plasma glucose (4 hours post OGTT) at later times than
the CP-inhibitor in animals. -- With chronic administration, PT-630
is differentiated from both the CP-inhibitor and metformin in
animals. After 44 days of daily dosing, PT-630 was more effective
than the other two study compounds in improving parameters
associated with the progression of type 2 diabetes. Specifically,
there were improvements in whole body sensitivity to insulin, a 50%
reduction in fasting plasma triglycerides and glucose levels and a
1.7% reduction (a 26.4% reduction compared to the controlled
treated group) in HbA1c. There were no such reductions in
triglycerides and glucose levels with metformin and the
CP-inhibitor, and HbA1c was only reduced by 0.9% and 0.5%,
respectively, with metformin and the CP-inhibitor. A copy of the
poster can be found on the Company's Web site www.pther.com. About
PT-630: PT-630, Point Therapeutics' lead diabetes compound, is an
inhibitor of DPP-4, which is a widely recognized target in the
treatment of diabetes. DPP-4 degrades the active form of GLP-1, an
intestinal peptide hormone responsible for regulating blood glucose
levels. When DPP-4 is inhibited, it leads to an elevation in the
circulating pool of active GLP-1, thereby greatly improving the
control of blood glucose levels in type 2 diabetes. Active GLP-1 is
also thought to have beneficial effects on pancreatic beta cell
mass. About Point Therapeutics, Inc.: Point is a Boston-based
biopharmaceutical company developing a portfolio of dipeptidyl
peptidase (DPP) inhibitors for use in cancer, type 2 diabetes and
as vaccine adjuvants. Point is currently studying its lead product
candidate, talabostat, in two Phase 3 trials in non-small cell lung
cancer. Point is also studying talabostat in several Phase 2
trials, including as a single-agent in metastatic melanoma, in
combination with cisplatin in metastatic melanoma, in combination
with rituximab in advanced chronic lymphocytic leukemia, and in
combination with gemcitabine in metastatic pancreatic cancer. In
addition, Point's portfolio includes two other DPP inhibitors in
preclinical development--PT-630 for type 2 diabetes and PT-510 as a
vaccine adjuvant. Certain statements contained herein are not
strictly historical and are "forward looking" statements as defined
in the Private Securities Litigation Reform Act of 1995. This
information includes statements with respect to the company's
clinical development programs and the timing of initiation and
completion of its clinical trials. Forward-looking statements are
statements that are not historical facts, and can be identified by,
among other things, the use of forward-looking language, such as
"believes," "feels," "expects," "may," "will," "should," "seeks,"
"plans," "schedules to," "projects," "anticipates" or "intends" or
the negative of those terms, or other variations of those terms of
comparable language, or by discussions of strategy or intentions. A
number of important factors could cause actual results to differ
materially from those projected or suggested in the forward looking
statement, including the risk factors described in Point's
quarterly report on Form 10-Q for the quarter ended March 31, 2006
and from time to time in Point's periodic and other reports filed
with the Securities and Exchange Commission.
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Jul 2023 to Jul 2024